Source-grounded facts extracted from TransMedics Group, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TransMedics Group, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-20 meeting.
“Proposal Four : The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026, based on the following votes:”
TransMedics Group, Inc. shareholders approved Amendment to Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan at the 2026-05-20 meeting.
“Proposal Three : The shareholders approved the amendment to the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, based on the following votes:”
TransMedics Group, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-05-20 meeting.
“Proposal Two : The shareholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, based on the following votes:”
TransMedics Group, Inc. shareholders approved Election of eight directors to serve until the 2027 Annual Meeting at the 2026-05-20 meeting.
“Proposal One : The shareholders elected Waleed Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Jr., Stephanie Lovell, Merilee Raines, and David Weill, M.D. as directors, each to serve on the Board of Directors of the Company until the 2027 Annual Meeting of Shareholders or until his or her successor is duly elected and qualified in accordance with our Restated Articles of Organization and Amended and Restated Bylaws, or his or her earlier death, resignation or removal, based on the following votes:”
TransMedics Group, Inc. reported the quarter ended March 31, 2026 results: revenue $173.9 million, net income $7.3 million, EPS $0.20 per fully diluted share. Guidance reaffirmed.
“Total revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025 ▪ Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026”
TransMedics Group, Inc. entered into Lease with BioMed Realty valued at approximately $23.9 million (effective 2026-01-08).
“On January 8, 2026, TransMedics Group, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with BioMed Realty (the “Landlord”) for the lease of approximately 498,286 square feet of space located at 188 Assembly Park Drive, Somerville, MA 02145 (the “Premises”)”
TransMedics Group, Inc. completed an acquisition involving Teaghlach Aviation, LLC for approximately $14.5 million (closed 2025-10-03).
“on October 3, 2025, the Buyer acquired a fixed-wing aircraft from Teaghlach Aviation, LLC for a purchase price of approximately $14.5 million”
TransMedics Group, Inc. completed an acquisition involving Ocean Select Seafood, L.L.C. for approximately $14.3 million (closed 2025-02-20).
“on February 20, 2025, the Buyer acquired a fixed-wing aircraft from Ocean Select Seafood, L.L.C. for a purchase price of approximately $14.3 million”
TransMedics Group, Inc. completed an acquisition involving RCS Leasing, LLC for approximately $14.1 million (closed 2025-01-08).
“Subsequently, on January 8, 2025, the Buyer acquired a fixed-wing aircraft from RCS Leasing, LLC for a purchase price of approximately $14.1 million”
TransMedics Group, Inc. completed an acquisition involving A-JETS CZ, a.s. for approximately $13.9 million (closed 2024-12-05).
“on December 5, 2024, the Buyer acquired a fixed-wing aircraft from A-JETS CZ, a.s. for a purchase price of approximately $13.9 million”
TransMedics Group, Inc. completed an acquisition involving 77 Aviation, LLC for approximately $14.4 million (closed 2024-09-06).
“on September 6, 2024, the Buyer acquired a fixed-wing aircraft from 77 Aviation, LLC for a purchase price of approximately $14.4 million”
TransMedics Group, Inc. completed an acquisition involving Butterfield Air, LLC for approximately $14.0 million (closed 2024-07-26).
“on July 26, 2024, the Buyer acquired a fixed-wing aircraft from Butterfield Air, LLC for a purchase price of approximately $14.0 million”
TransMedics Group, Inc. reported quarter ended March 31, 2024 results: revenue $96.9 million, net income $12.2 million, EPS $0.35 per fully diluted share. Guidance raised.
“Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023”
TransMedics Group, Inc. completed an acquisition involving Evans General Aviation, LLC for approximately $12.5 million (closed 2024-03-08).
“on March 8, 2024, the Buyer acquired a fixed-wing aircraft from Evans General Aviation, LLC for a purchase price of approximately $12.5 million (together with the Prior Acquisitions, the “Acquisitions”).”
TransMedics Group, Inc. reported full-year 2024 results: revenue $360 million to $370 million. Guidance initiated.
“TransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company’s prior year revenue.”
TransMedics Group, Inc. reported the year ended December 31, 2023 results: revenue $241.6 million, net income $(25.0) million.
“December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the full year of 2022 ▪ Generated net income of $4.0 million or $0.12 per share in the fourth quarter of 2023 “2023 was a”
TransMedics Group, Inc. reported the quarter ended December 31, 2023 results: revenue $81.2 million, net income $4.0 million, EPS $0.12 per share.
“patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the”
TransMedics Group, Inc. completed an acquisition involving Fly1212V LLC for purchase price of approximately $13.5 million (closed 2024-02-02).
“On February 2, 2024, the Buyer acquired a fixed-wing aircraft from Fly1212V LLC for a purchase price of approximately $13.5 million”
TransMedics Group, Inc. completed an acquisition involving Hurricane Express Logistics, Inc. for approximately $13.1 million (closed 2024-01-25).
“Subsequently, on January 25, 2024, the Buyer acquired a fixed-wing aircraft from Hurricane Express Logistics, Inc. for a purchase price of approximately $13.1 million”
TransMedics Group, Inc. completed an acquisition involving Munday Aviation, LLC for approximately $13.2 million (closed 2023-12-18).
“on December 18, 2023, the Buyer acquired a fixed-wing aircraft from Munday Aviation, LLC for a purchase price of approximately $13.2 million”
TransMedics Group, Inc. completed an acquisition involving Hurricane Express Logistics, Inc. for approximately $12.9 million (closed 2023-11-09).
“on November 9, 2023, the Buyer acquired a fixed-wing aircraft from Hurricane Express Logistics, Inc. for a purchase price of approximately $12.9 million”
TransMedics Group, Inc. amended Third Amendment with Canadian Imperial Bank of Commerce valued at $300.0 million (effective 2023-11-09).
“On November 9, 2023, TransMedics Group, Inc. (the “Company”) entered into a third amendment to the credit agreement (the “Third Amendment”), which amends that certain credit agreement, dated as of July 25, 2022 (as amended by the First Amendment to Credit Agreement, dated as of May 8, 2023, as further amended by the Second Amendment to Credit Agreement, dated as of June 23, 2023, the “Credit Agreement”), with Canadian Imperial Bank of Commerce (“CIBC”), which, among other items, permits the Company to make acquisitions of equity or assets of another entity, subject to the conditions under the Third Amendment, without further consent of CIBC, for cash consideration in a maximum aggregate amount for all such acquisitions of $300.0 million.”
TransMedics Group, Inc. reported quarter ended September 30, 2023 results: revenue $66.4 million. Guidance raised.
“therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023. Recent Highlights ▪ Net revenue of $66.4 million in the third quarter of 2023, a 159% increase compared to the third quarter of 2022, including $1.6 million non-recurring charter revenue ▪ Closed acquisition of Summit Aviation,”
TransMedics Group, Inc. completed an acquisition involving FW Equipment Leasing, LLC for approximately $13.4 million (closed 2023-09-21).
“the Buyer acquired a fixed-wing aircraft from FW Equipment Leasing, LLC for a purchase price of approximately $13.4 million (the "Seventh Acquisition")”
TransMedics Group, Inc. completed an acquisition involving Hurricane Express Logistics, Inc. for purchase price of approximately $13.3 million (closed 2023-09-07).
“on September 7, 2023, the Buyer acquired a fixed-wing aircraft from Hurricane Express Logistics, Inc. for a purchase price of approximately $13.3 million (the "Fifth Acquisition")”
TransMedics Group, Inc. completed an acquisition involving Mountain Snow Management, LLC for approximately $12.6 million (closed 2023-09-01).
“on September 1, 2023, the Buyer acquired a fixed-wing aircraft from Mountain Snow Management, LLC for a purchase price of approximately $12.6 million (the "Third Acquisition")”
TransMedics Group, Inc. reported full year 2023 results: revenue $180 million to $190 million. Guidance raised.
“TransMedics is updating its full year 2023 revenue guidance to be in the range of $180 million to $190 million, which represents 93% to 103% growth compared to the company’s prior year revenue. TransMedics’ prior 2023 revenue guidance was $160 million to $170 million.”
TransMedics Group, Inc. reported quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022..
“Net revenue of $52.5 million in the second quarter of 2023, a 156% increase compared to the second quarter of 2022 .”
TransMedics Group, Inc. amended Second Amendment with Canadian Imperial Bank of Commerce (effective 2023-06-23).
“On June 23, 2023, TransMedics Group, Inc. (the “Company”) entered into a second amendment to the credit agreement (the “Second Amendment”), which amends that certain credit agreement, dated as of July 25, 2022”
TransMedics Group, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2023 at the 2023-05-25 meeting.
“Proposal Four : The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023, based on the following votes: For Against Abstain 26,378,751 546,315 9,297”
TransMedics Group, Inc. shareholders approved Approval of Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan at the 2023-05-25 meeting.
“Proposal Three : The shareholders approved the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, based on the following votes: For Against Abstain Broker Non-Votes 19,996,361 4,483,557 21,292 2,433,153”
TransMedics Group, Inc. shareholders approved Advisory vote on executive compensation at the 2023-05-25 meeting.
“Proposal Two : The shareholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, based on the following votes: For Against Abstain Broker Non-Votes 22,963,086 1,519,849 18,275 2,433,153”
TransMedics Group, Inc. shareholders approved Election of eight directors to serve until the 2024 annual meeting at the 2023-05-25 meeting.
“Proposal One : The shareholders elected Waleed H. Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Stephanie Lovell, Merilee Raines and David Weill, M.D. as directors, each to serve on the board of directors of the Company until the 2024 annual meeting of the Company’s shareholders to be held in 2024 or until his or her successor is duly elected and qualified in accordance with our restated articles of organization and second amended and restated bylaws, or his or her earlier death, resignation or removal, based on the following votes: Director Nominee For Against Abstain Broker Non-Votes Waleed H. Hassanein, M.D 24,276,377 218,114 6,719 2,433,153 James R. Tobin 22,266,327 2,227,909 6,974 2,433,153 Edward M. Basile 19,270,950 5,222,893 7,367 2,433,153 Thomas J. Gunderson 24,375,647 118,498 7,065 2,433,153 Edwin M. Kania 24,144,520 349,634 7,056 2,433,153 Stephanie Lovell 23,196,175 1,298,370 6,665 2,433,153 Merilee Raines 24,372,323 122,126 6,761”
TransMedics Group, Inc. incurred convertible notes of $400.0 million aggregate principal amount with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC at 1.50% maturing June 1, 2028.
“On May 8, 2023, TransMedics Group, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with the several initial purchasers named in Schedule I thereto (the “Initial Purchasers”), for whom Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC acted as representatives (the “Representatives”) relating to the sale of $400.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2028 (the “Notes”) to the Initial Purchasers.”
TransMedics Group, Inc. entered into Indenture with U.S. Bank Trust Company, National Association (effective 2023-05-11).
“The Notes were issued by the Company on May 11, 2023 pursuant to an Indenture, dated as of such date (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).”
TransMedics Group, Inc. entered into Purchase Agreement with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC valued at $400.0 million aggregate principal amount (effective 2023-05-08).
“On May 8, 2023, TransMedics Group, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with the several initial purchasers named in Schedule I thereto (the “Initial Purchasers”), for whom Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC acted as representatives (the “Representatives”) relating to the sale of $400.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2028 (the “Notes”) to the Initial Purchasers.”
TransMedics Group, Inc. amended Credit Agreement Amendment with Canadian Imperial Bank of Commerce valued at amended certain covenants and other provisions to enable issuance of 1.50% Convertible Senior Notes (effective 2023-05-08).
“On May 8, 2023, we entered into an amendment to the credit agreement (the “Amendment”), which amends that certain credit agreement dated as of July 25, 2022 (the “Credit Agreement”), with Canadian Imperial Bank of Commerce, which among other items, amended certain covenants and other provisions under the Credit Agreement to enable the issuance of our 1.50% Convertible Senior Notes due 2028 and to permit us to enter into privately negotiated capped call transactions, subject to the terms and conditions under the Amendment.”
TransMedics Group, Inc. reported the quarter ended March 31, 2023 results: revenue $41.6 million, net income $2.6 million, EPS $(0.34) per diluted share. Guidance raised.
“TransMedics Reports First Quarter 2023 Financial Results Andover, Mass. – May 1, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights ▪ Net revenue of $41.6 million in the first quarter of 2023, a 162% increase compared to the first quarter of 2022”
TransMedics Group, Inc. reported Full year 2023 results: revenue $138 million to $145 million. Guidance initiated.
“TransMedics expects total revenue for full-year 2023 to be in the range of $138 million to $145 million, which represents 48% to 55% growth compared to the company’s prior year revenue.”
TransMedics Group, Inc.: Amended Bylaws to update procedural requirements for director nominations reflecting SEC's universal proxy rules and other administrative changes (effective 2022-11-02).
“On November 2, 2022, the Board of Directors (the “Board”) of TransMedics Group, Inc. (the “Company”) approved the Company’s Second Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”), effective as of such date.”
TransMedics Group, Inc. reported full year 2022 results: revenue $80 million to $85 million. Guidance raised.
“TransMedics is updating full year 2022 revenue to be in the range of $80 million to $85 million, excluding the $1.4 million favorable change in estimate for contra revenue, which represents 164% to 181% growth compared to the company’s prior year revenue.”
TransMedics Group, Inc. reported the quarter ended September 30, 2022 results: revenue $25.7 million, net income $7.4 million.
“Net revenue for the third quarter of 2022 was $25.7 million, a 378% increase compared to $5.4 million in the third quarter of 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.